[1]
|
Jemal, A., Siegel, R., Ward, E., et al. (2008) Cancer statistics, 2008. CA: A Cancer Journal for Clinicians, 58, 71-96. doi:10.3322/CA.2007.0010
|
[2]
|
Soda, M., Choi, Y.L., Enomoto, M., et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature, 448, 561-566.
doi:10.1038/nature05945
|
[3]
|
Schiller, J.H., Harrington, D., Belani, C.P., et al. (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. The New England Journal of Medicine, 346, 92-98. doi:10.1056/NEJMoa011954
|
[4]
|
Lynch, T.J., Bell, D.W., Sordella, R., et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancerto gefitinib. The New England Journal of Medicine, 350, 2129-2139. doi:10.1056/NEJMoa040938
|
[5]
|
Mok, T., Wu, Y.-L., Thongprasert, S., et al. (2008) Phase III, randomized, open-label, first line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer (IPASS). 33rd European Society for Medical Oncology Congress, Stockholm, 12-16 September 2008.
|
[6]
|
Soda, M., Choi, Y.L., Enomoto, M., et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature, 448, 561-566.
doi:10.1038/nature05945
|
[7]
|
Chiarle, R., Voena, C., Ambrogio, C., et al. (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nature Reviews Cancer, 8, 11-23. doi:10.1038/nrc2291
|
[8]
|
Rikova, K., Guo, A., Zeng, Q., et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 131, 1190-1203.
doi:10.1016/j.cell.2007.11.025
|
[9]
|
Koivunen, J.P., Mermel, C., Zejnullahu, K., et al. (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clinical Cancer Research, 14, 4275-4283. doi:10.1158/1078-0432.CCR-08-0168
|
[10]
|
Kwak, E.L., Camidge, D.R., Clark, J., et al. (2009) Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. Journal of Clinical Oncology, 27, 3509
|
[11]
|
Kwak, E.L., Bang, Y.-J., Camidge, D.R., et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England Journal of Medicine, 29, e443-e445
|
[12]
|
Camidge, D.R., Bang, Y., Kwak, E.L., et al. (2011) Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive nonsmall cell lung cancer (NSCLC). Journal of Clinical Oncology, 29, 2501.
|
[13]
|
Shaw, A.T., Yeap, B.Y., Kenudson-Mino, M., et al. (2009) Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK. Journal of Clinical Oncology, 27, 4247-4253.
doi:10.1200/JCO.2009.22.6993
|
[14]
|
Shinmura, K., Kageyama, S., Tao, H., et al. (2008) EML4 ALK fusion transcripts, but no NPM, TPM3, CLTC, ATIC, or TGF-ALK fusion transcripts, in non-small cell lung carcinoma. Lung Cancer, 61, 163-169.
doi:10.1016/j.lungcan.2007.12.013
|
[15]
|
Martini N, Melamed MR. Multiple primary lung cancer. J Thorac Cardiovasc Surg.1975;70:606-12
|
[16]
|
Wang, X., Christiani, D.C., Mark, E.J., et al. (1999) Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma. Cancer, 85, 1734-1739.
doi:10.1002/(SICI)1097-0142(19990415)85:8<1734::AID-CNCR13>3.0.CO;2-1
|
[17]
|
Rostad, H., Strand, T.E., Naalsund, A. and Norstein, J. (2008) Resected synchronous primary malignant lung tumors: A population-based study. The Annals of Thoracic Surgery, 85, 204-209.
doi:10.1016/j.athoracsur.2007.07.091
|